39P Preliminary clinical investigations and mechanism exploration of furmonertinib in NSCLC with EGFR exon 20 insertion

医学 奥西默替尼 内科学 第一行 肿瘤科 胃肠病学 外科 表皮生长因子受体 癌症 埃罗替尼
作者
X. Zhang,G. Feng,H. Han,B. Dong,Y. Yang,H. Zhu,S. Fan,H. Tang
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:18 (4): S63-S63
标识
DOI:10.1016/s1556-0864(23)00293-9
摘要

Here we analyzed the clinical efficacy of furmonertinib, a novel 3rd generation EGFR TKI, in advanced NSCLC patients (pts) who harboring EGFRex20ins and explored mechanism. A retrospective single-arm analysis was performed to evaluate the efficacy of 20 NSCLC pts harboring EGFRex20ins receiving furmonertinib treatment from three institutions. Meanwhile, we investigated the clinical efficacy of furmonertinib versus osimertinib as second-line treatment, because pts about furmonertinib as first-line treatment were immature. In addition, the binding activity of different EGFR TKIs to EGFRex20ins were computationally constructed based on the crystal structure of EGFR_D770_N771insNPG/V948R (PDB ID: 7LGS) by the Schrödinger software (2021–2 Release). Of the 20 pts selected, we found that EGFRex20ins p. S768_D770dup (n = 5) variants were more common. Six first-line pts all achieved PR (ORR: 100%), five of the eight second-line pts achieved PR (ORR: 62.5%), and three of the six multiple-line pts achieved PR (ORR: 50.0%). We observed 14 pts with PR and six pts with SD as best response to furmonertinib (ORR: 70.0%, DCR: 100%). All pts showed tumor shrinkage in target lesions (median best percent change, –36.43% [–74.78%, –5.56%]). Median PFS was 10.2 (95% CI, 7.19–13.21) months (mo). Median DOR was 8.5 (95% CI, 4.97–12.03) mo. Comparative analysis of the efficacy of different groups showed that median PFS was significantly longer in furmonertinib group than in osimertinib (10.2 vs 3.8 mo, p = 0.008). Median OS was numerically longer in furmonertinib group than in osimertinib (18.9 vs 11.7 mo, p = 0.207). No grade 3 or above adverse events were observed. Furthermore, rather than erlotinib (GlideScore: –5.564; MM/GBSA: –52.8044), gefitinib (–7.68; –47.317), and afatinib (–5.075; –44.64), furmonertinib (–11.085; –68.1575) and osimertinib (–10.031; –63.87) revealed favorable binding activity to EGFRex20ins, with furmonertinib being the most significant. Furmonertinib has positive clinical efficacy to advanced NSCLC pts with EGFRex20ins probably based on its favorable binding activity to EGFRex20ins. Furmonertinib may be the optimal choice for these pts in the future.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
浪费青春传奇完成签到 ,获得积分10
2秒前
少女徐必成完成签到 ,获得积分10
2秒前
健壮的思枫完成签到,获得积分10
3秒前
棱擎1号完成签到 ,获得积分10
4秒前
6秒前
tian发布了新的文献求助10
6秒前
panpanliumin完成签到,获得积分0
7秒前
普鲁卡因发布了新的文献求助10
9秒前
Keyuuu30完成签到,获得积分0
9秒前
9秒前
学者风范完成签到 ,获得积分10
11秒前
进退须臾完成签到,获得积分10
12秒前
图图发布了新的文献求助10
12秒前
liujinjin完成签到,获得积分10
13秒前
甜甜醉波完成签到,获得积分10
13秒前
小不完成签到 ,获得积分10
14秒前
小心薛了你完成签到,获得积分10
20秒前
与离完成签到 ,获得积分10
20秒前
感性的俊驰完成签到 ,获得积分10
24秒前
疯狂的凡梦完成签到 ,获得积分10
25秒前
桥豆麻袋完成签到,获得积分10
26秒前
量子星尘发布了新的文献求助10
27秒前
Hello应助幸福的杨小夕采纳,获得10
27秒前
Lighten完成签到 ,获得积分10
28秒前
lyj完成签到 ,获得积分10
29秒前
成就茗完成签到 ,获得积分10
31秒前
ZD完成签到 ,获得积分10
40秒前
42秒前
英姑应助普鲁卡因采纳,获得10
45秒前
冰糕发布了新的文献求助10
47秒前
BettyNie完成签到 ,获得积分10
49秒前
优雅的平安完成签到 ,获得积分10
49秒前
冰糕完成签到,获得积分10
54秒前
56秒前
852应助完犊子采纳,获得10
1分钟前
ruochenzu发布了新的文献求助10
1分钟前
不想洗碗完成签到 ,获得积分10
1分钟前
const完成签到,获得积分10
1分钟前
hjx完成签到 ,获得积分10
1分钟前
稳重的尔安完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022